

Published in final edited form as:

*Science*. 2010 October 8; 330(6001): 228–231. doi:10.1126/science.1196333.

## Frequent Mutations of Chromatin Remodeling Gene *ARID1A* in Ovarian Clear Cell Carcinoma

Siân Jones<sup>1</sup>, Tian-Li Wang<sup>2</sup>, Ie-Ming Shih<sup>3</sup>, Tsui-Lien Mao<sup>4</sup>, Kentaro Nakayama<sup>5</sup>, Richard Roden<sup>3</sup>, Ruth Glas<sup>6</sup>, Dennis Slamon<sup>6</sup>, Luis A. Diaz Jr<sup>1</sup>, Bert Vogelstein<sup>1</sup>, Kenneth W. Kinzler<sup>1,†</sup>, Victor E. Velculescu<sup>1,†</sup>, and Nickolas Papadopoulos<sup>1,†</sup>

<sup>1</sup>Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA

<sup>2</sup>Department of Gynecology and Obstetrics and Oncology, Johns Hopkins Medical Institutes, Baltimore, MD 21231, USA

<sup>3</sup>Department of Pathology, Oncology, Gynecology and Obstetrics, Johns Hopkins Medical Institutes, Baltimore, MD 21231, USA

<sup>4</sup>Department of Pathology, National Taiwan University College of Medicine, Taipei, Taiwan

<sup>5</sup>Department of Gynecology and Obstetrics, Shimane University, Izumo, Japan

<sup>6</sup>Division of Hematology/Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA 99095, USA

### Abstract

Ovarian Clear Cell Carcinoma (OCCC) is an aggressive human cancer that is generally resistant to therapy. To explore the genetic origin of OCCC, we determined the exomic sequences of eight tumors after immunoaffinity purification of cancer cells. Through comparative analyses of normal cells from the same patients, we identified four genes that were mutated in at least two tumors. *PIK3CA*, which encodes a subunit of phosphatidylinositol-3 kinase, and *KRAS*, which encodes a well known oncoprotein, had previously been implicated in OCCC. The other two mutated genes were novel: *PPP2R1A* encodes a regulatory subunit of serine/threonine phosphatase 2 and *ARID1A* encodes AT-rich interactive domain-containing protein 1A, which participates in chromatin remodeling. The nature and pattern of the mutations suggest that *PPP2R1A* functions as an oncogene and *ARID1A* as a tumor suppressor gene. In a total of 42 OCCCs, 7% had mutations in *PPP2R1A* and 57% had mutations in *ARID1A*. These results suggest that aberrant chromatin remodeling contributes to the pathogenesis of OCCC.

Ovarian cancers are a heterogeneous group of diseases with distinct clinicopathological and molecular features (1). Among them, OCCCs, which accounts for 10% of epithelial ovarian cancers, is one of the most aggressive types because, unlike the high grade-serous type, it is refractory to standard platinum-based chemotherapy. Previous morphological and molecular studies have indicated that OCCC develops in a stepwise fashion from a common disease progenitor state, in many cases endometriosis, and then proceeds to frank malignancy (2-6). Activating mutations in *PIK3CA* (7) and genomic amplification of chr20q13.2 (8) are the most common molecular genetic alterations so far identified in OCCC.

<sup>†</sup>To whom correspondence should be addressed. npapado1@jhmi.edu (N.P.); kinzke@jhmi.edu (K.W.K.); velculescu@jhmi.edu (V.E.V.).

To explore the genetic basis of this tumor type, we have determined the sequences of the ~18,000 protein-encoding genes listed in the RefSeq database in tumors from eight patients (table S1). Because these tumors are composed of a mixture of cancer and stromal cells, we purified the cancer cells using epithelial cell target antibodies attached to magnetic beads (9). Staining of the cells bound to the beads revealed that > 90% of them were OCCC cells. This procedure thereby maximized the sensitivity of the sequencing analyses by eliminating most of the contaminating normal cells (containing normal genomes) from the sample. DNA from the purified cells, as well as from normal cells obtained from the blood or uninvolved tissues of the same patients were used to generate libraries suitable for massively parallel sequencing by synthesis (9). Following capture of the coding sequences of the targeted genes with a SureSelect Enrichment System, the DNA was sequenced using an Illumina GAIIx platform. The average coverage of each base in the targeted regions was 84 fold and 92.7 % of these bases were represented in at least 10 reads (table S2).

Using stringent criteria for analysis of these data (9) we identified 268 somatic mutations in 253 genes among the eight tumors. The range of mutations per tumor was 13 to 125 alterations. Of these, 237 (88%) mutations were confirmed by Sanger sequencing (table S3). The tumor with 125 mutations (OCC06PT) was from a patient with recurrent disease that had previously been treated with chemotherapy. Excluding OCC06PT, there was an average of 20 mutations per tumor (table S2 and S3). The mutation spectrum was enriched for C to T transitions at 5'-CG base pairs, similar to those of other tumors whose exomes have been sequenced (10-14). Only four genes were mutated in more than one of the eight tumors studied: *PIK3CA*, *KRAS*, *PPP2RIA*, and *ARIDIA*. The mutations in each of these four genes, and their somatic nature, were confirmed by Sanger sequencing of the DNA from the tumor and normal tissues of the corresponding patients (examples in Fig. 1). The sequences of these four genes were then determined in the tumor and normal tissues of an additional 34 OCCC cases using PCR amplification and Sanger sequencing with the primers listed in table S4. In total, *PIK3CA*, *KRAS*, *PPP2RIA*, and *ARIDIA* mutations were identified in 40%, 4.7%, 7.1%, and 57% of the 42 tumors, respectively (Table 1).

Cancer cell lines with mutations in genes involved in cancer development provide valuable tools for further research. To this end, we extended the analysis of these four genes in seven OCCC cell lines that were derived from tumors independent of those described above. In seven cell lines we identified nine *ARIDIA* mutations in five cell lines, three with *PPP2RIA* mutations, one with a *KRAS* mutation and four with *PIK3CA*, mutations (table S5).

The nature of the somatic mutations in tumors can often be used to classify them as oncogenes or tumor suppressor genes (15). In particular, all bona fide oncogenes are mutated recurrently (that is, at the same codon or clustered at a few adjacent codons in different tumors), and the mutations are nearly always missense. In contrast, all bona fide tumor suppressor genes are mutated at a variety of positions throughout the coding region of the gene and the mutations often truncate the encoded protein through production of a stop codon by a base substitution, an out-of-frame insertion or deletion (indel) or a splice site mutation. Moreover, tumor suppressor gene mutations generally affect both alleles, whereas mutations in oncogenes commonly affect only one allele.

Based on this logic, we can speculate about the likely function of the four genes in OCCC. *PIK3CA* and *KRAS* are well-studied oncogenes, and the 19 mutations identified in OCCC were heterozygous and clustered; fourteen of the 17 mutations in *PIK3CA* were at codons 542, 546, or 1047, while both mutations in *KRAS* were at codon 12 (Table 1). The three mutations in *PPP2RIA* were similarly heterozygous and clustered, suggesting that it functions, when mutated, as an oncogene (Table 1). In contrast, the 32 mutations in *ARIDIA* were distributed throughout the coding region and all were predicted to truncate the protein

through a base substitution resulting in a stop codon (9 mutations), or an out-of-frame insertion or deletion (23 mutations) (Table 1). In 10 of the 24 tumors with *ARID1A* mutations, both *ARID1A* alleles were affected through either a mutation in one allele and loss of heterozygosity of the other allele, or through two mutations which were presumably biallelic. Thus, we hypothesize that *ARID1A* functions as a tumor suppressor gene and that somatic mutations inactivate the gene product.

The serine/threonine protein phosphatase PP2A represents a family of holoenzymes with various activities. The holoenzyme contains a core composed of a heterodimer of a catalytic subunit (PPP2CA or PPP2CB) and a constant regulatory subunit (PPP2R1A or PPP2R1B). PPP2R1A serves as a scaffold to coordinate the interaction of the core enzyme with one of more than 15 regulatory subunits to form the heterotrimeric holoenzyme (16,17). Somatic mutations in *PPP2R1A* are not listed in the Cancer Gene Census of the COSMIC database, although a few alterations in this gene have been previously reported (18). Functional studies have shown that PP2A is involved in the control of cell growth and division. Specifically, this protein is required for proper chromosome segregation through its interactions with Bub1 and Sgo1 (19). The two arginine residues that were somatically mutated in OCCC are highly conserved and reside within one of the HEAT domains of PPP2R1A that are involved in binding regulatory subunits.

The protein encoded by *ARID1A* can bind to AT-rich DNA sequences and is a component of the ATP-dependent chromatin modeling complex SWI/SNF. The SWI/SNF chromatin-remodeling complex mobilizes nucleosomes and functions as a regulator of gene expression and chromatin dynamics. *ARID1A* is one of the two mutually exclusive *ARID1* subunits of the SWI/SNF complex and is thought to provide specificity to this complex (20). Changes in chromatin can influence the epigenetic regulation of many genes, inducing those that play a role in cancer (20-22). Indeed, functional studies have implicated *ARID1A* in the ability of the SWI/SNF complex to inhibit cell growth (23). No mutations of *ARID1A* are listed in the Cancer Gene Census of the COSMIC database, but chromosomal translocations that involve this gene have been identified in a human breast cancer and a human lung cancer cell line (24). Knock-down of *ARID1A* in a leukemia cell line confers resistance to Fas-mediated apoptosis (25).

The results of this study emphasize two themes in modern cancer genetics. The first is that specific tumor types are characterized by mutations in “communal cancer genes” like *KRAS* and *PIK3CA* as well as in “restricted cancer genes” like *PPP2R1A* and *ARID1A*. The communal cancer genes are involved in a variety of cancers and have been extensively studied. Restricted cancer genes have been shown to contribute to specific types of leukemias and sarcomas, mainly through translocations (e.g., the *ABL* oncogene in chronic myelogenous leukemia and *EWS* fused to an *ETS* transcription factor family member in Ewing's sarcoma). With the advent of whole exome sequencing, we are beginning to see similar specificity with respect to point mutations (e.g., *IDH1* in gliomas (14) and *GNAQ* in uveal melanomas (26)).

The second theme is that mutations of chromatin-modifying genes are characteristic of certain tumor types. Recent examples include the *JARID1C* gene, also known as lysine (K)-specific demethylase 5C (*KDM5C*), in renal cell cancers (27), *SMARCA4/BRG1* (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) in lung cancers (28) and now *ARID1A* in OCCC. Epigenetic changes in cancers, including methylation of deoxycytidine residues in DNA and a variety of covalent modifications of chromatin proteins, have been extensively studied (20-22,29). Interestingly, however, the reason(s) that DNA methylation and chromatin are different in cancer cells than in normal cells is completely unknown. Similarly, the relationship between the genetic alterations that

unequivocally drive tumorigenesis and the epigenetic changes that are so widespread in tumor genomes has not been defined. Discovery of tumor suppressor genes such as *ARID1A* that are mutated in cancers bridge this gap, as they are likely to directly lead to epigenetic changes in cancer cells through specific modifications of chromatin proteins. They additionally provide a potential approach to determine which of the numerous epigenetic changes in cancers confer a selective growth advantage and which are simply “passengers” that do not play a causal role. The identification of the genes whose chromatin is specifically affected by *ARID1A* inactivation, and whose expression is thereby modulated, will be the next crucial step in this line of research.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

We thank Y. He for technical advice and M. Whalen, J. Ptak, and N. Silliman for expert technical assistance. Funded by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, AACR Stand Up To Cancer-Dream Team Translational Cancer Research Grant, The Virginia and D. K. Ludwig Fund for Cancer Research, US Department of Defense grant OC0400600 (TLW), and NIH grants CA121113, CA57345, CA129080, CA103937 (IMS), CA122581 (RR).

## References

1. Cho KR, Shih Ie M. *Annu Rev Pathol.* 2009; 4:287. [PubMed: 18842102]
2. Erzen M, Rakar S, Klančnik B, Syrjanen K. *Gynecol Oncol.* 2001; 83:100. [PubMed: 11585420]
3. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. *Histopathology.* 1997; 30:249. [PubMed: 9088954]
4. Marquez RT, et al. *Clin Cancer Res.* 2005; 11:6116. [PubMed: 16144910]
5. Sato N, et al. *Cancer Res.* 2000; 60:7052. [PubMed: 11156411]
6. Veras E, et al. *Am J Surg Pathol.* 2009; 33:844. [PubMed: 19342944]
7. Kuo KT, et al. *Am J Pathol.* 2009; 174:1597. [PubMed: 19349352]
8. Kuo KT, et al. *Clin Cancer Res.* 2010; 16:1997. [PubMed: 20233889]
9. See supporting material on *Science* Online.
10. Greenman C, et al. *Nature.* 2007; 446:153. [PubMed: 17344846]
11. Sjoblom T, et al. *Science.* 2006; 314:268. [PubMed: 16959974]
12. Wood LD, et al. *Science.* 2007; 318:1108. [PubMed: 17932254]
13. Jones S, et al. *Science.* 2008; 321:1801. [PubMed: 18772397]
14. Parsons DW, et al. *Science.* 2008; 321:1807. [PubMed: 18772396]
15. Vogelstein B, Kinzler KW. *Nat Med.* 2004; 10:789. [PubMed: 15286780]
16. Eichorn PJ, Creighton MP, Bernards R. *Biochim Biophys Acta.* 2009; 1795:1. [PubMed: 18588945]
17. Shi Y. *Cell.* 2009; 139:468. [PubMed: 19879837]
18. Calin GA, et al. *Oncogene.* 2000; 19:1191. [PubMed: 10713707]
19. Tang Z, et al. *Dev Cell.* 2006; 10:575. [PubMed: 16580887]
20. Wu JI, Lessard J, Crabtree GR. *Cell.* 2009; 136:200. [PubMed: 19167321]
21. Weissamn B, Knudsen KE. *Cancer Res.* 2009; 69:8223. [PubMed: 19843852]
22. Banine F, et al. *Cancer Res.* 2005; 65:3542. [PubMed: 15867346]
23. Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E. *Embo J.* 2007; 26:752. [PubMed: 17255939]
24. Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. *Genes Chromosomes Cancer.* 2007; 46:745. [PubMed: 17492758]

25. Luo B, et al. Proc Natl Acad Sci U S A. Dec 23.2008 105:20380. [PubMed: 19091943]
26. Van Raamsdonk CD, et al. Nature. 2009; 457:599. [PubMed: 19078957]
27. Dalgliesh GL, et al. Nature. 2010; 463:360. [PubMed: 20054297]
28. Medina PP, et al. Huma Mutat. 2008; 29:617.
29. Jones PA, Baylin SB. Cell. 2007; 128:683. [PubMed: 17320506]



**Figure 1.** Sequence chromatograms showing somatic *ARID1A* and *PPP2R1A* mutations. The lower panels show the tumor and the upper panels show the matched normal control.

Table 1

Mutations in *ARID1A*, *KRAS*, *PIK3CA* and *PPP2R1A* in Human Ovarian Clear Cell Carcinomas.

Sample#	Gene	Transcript Accession	Nucleotide (genomic)*	Nucleotide (cDNA)	Amino acid (protein)	Mutation type
OCC01PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26972561_26972562insA	c.3854_3855insA	fs	Indel
OCC02PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26896034C>T	c.553C>T	p.Q185X	Nonsense
OCC02PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26978879-26978880dupGT	c.903_904dupGT	fs	Indel
OCC03PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26972009_26972034delTGATGGGGCGCATGTCTTATGAGCCA (hom)	c.3659_3684delTGATGGGGCGCATGTCTTATGAGCCA	fs	Indel
OCC07PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26896066C>A	c.585C>A	p.Y195X	Nonsense
OCC08PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26970389delC	c.3391delC	fs	Indel
OCC10PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26972790_26972792dupGCA (hom)	c.4001_4002dupGCA (hom)	fs	Indel
OCC10PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26979804_26979805delTG (hom)	c.6828_6829delTG (hom)	fs	Indel
OCC11PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26930334_26930335insCCTAC	c.1455_1466insCCTAC	fs	Indel
OCC13PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26974233_26974234insTGGC	c.4926_4927insTGGC	fs	Indel
OCC14PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26972886_26972887_deITT (hom)	c.4011_4012delITT (hom)	fs	Indel
OCC15PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26973940G>A	c.4635G>A	p.W1545X	Nonsense
OCC15PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26978178T>A	c.5202T>A	p.Y1734X	Nonsense
OCC16PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26895967_26895973delICGCCGCC (hom)	c.486_492delICGCCGCC (hom)	fs	Indel
OCC18PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26971925delA	c.3575delA	fs	Indel
OCC20PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26970221delG	c.3223delG	fs	Indel
OCC22PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26979694dupG	c.6718dupG	fs	Indel
OCC23PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26896379_2689637980_insCGTC	c.898_899insCGTC	fs	Indel
OCC23PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26979686_26979687insT	c.6710_6711insT	fs	Indel
OCC24PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26930542C>T	c.1663C>T	p.Q555X	Nonsense
OCC27PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26896263_26896272delICGTCGTCCTTC	c.782_791delICGTCGTCCTTC	fs	Indel
OCC27PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26971984_26971994delICAGCCCAAGTAT	c.3634_3644delICAGCCCAAGTAT	fs	Indel
OCC30PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26931823C>T	c.1873C>T	p.Q625X	Nonsense
OCC32PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26960135C>T	c.2122C>T	p.Q708X	Nonsense
OCC34PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26931754G>T	c.1804G>T	p.E602X	Nonsense
OCC34PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26979678delIT	c.6702delIT	fs	Indel
OCC36PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26928932T>G	c.1341T>G	p.Y447X	Nonsense
OCC36PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26971613delC	c.3442delC	fs	Indel

Sample#	Gene	Transcript Accession	Nucleotide (genomic)*	Nucleotide (cDNA)	Amino acid (protein)	Mutation type
OCC39PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26896364dupC	c.883dupC	fs	Indel
OCC39PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26965434delC	c.2868delC	fs	Indel
OCC41PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26931831delT	c.1881delT	fs	Indel
OCC42PT	<i>ARID1A</i>	CCDS285.1	g.chr1:26960479_26960488delCGGCCACCCA	c.2179_2188delCGGCCACCCA	fs	Indel
OCC04PT	<i>KRAS</i>	CCDS8703.1	g.chr12:25289551C>T	c.35G>A	p.G12D	Missense
OCC05PT	<i>KRAS</i>	CCDS8703.1	g.chr12:25289551C>G	c.35G>C	p.G12A	Missense
OCC01PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180418788C>A	c.1636C>A	p.Q546K	Missense
OCC02PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180418776G>A	c.1624G>A	p.E542K	Missense
OCC06PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180418785G>A	c.1633G>A	p.E545K	Missense
OCC08PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180418785G>A	c.1633G>A	p.E545K	Missense
OCC09PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180434779A>T	c.3140A>T	p.H1047L	Missense
OCC10PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180434779A>G	c.3140A>G	p.H1047R	Missense
OCC11PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180418777A>T	c.1625A>T	p.E542V	Missense
OCC13PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180434779A>G	c.3140A>G	p.H1047R	Missense
OCC15PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180410152C>G	c.1221C>G	p.C407W	Missense
OCC20PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180434779A>G	c.3140A>G	p.H1047R	Missense
OCC22PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180434779A>G	c.3140A>G	p.H1047R	Missense
OCC23PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180399648_180399649insCCTCAA	c.341_342msCCTCAA	fs	Indel
OCC27PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180399638A>G	c.331A>G	p.K111E	Missense
OCC30PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180434779A>G	c.3140A>G	p.H1047R	Missense
OCC35PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180418776G>A	c.1624G>A	p.E542K	Missense
OCC36PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180418785G>A	c.1633G>A	p.E545K	Missense
OCC42PT	<i>PIK3CA</i>	CCDS43171.1	g.chr3:180434779A>G	c.3140A>G	p.H1047R	Missense
OCC05PT	<i>PPP2RIA</i>	CCDS12849.1	g.chr19:57407794C>G	c.547C>G	p.R183G	Missense
OCC07PT	<i>PPP2RIA</i>	CCDS12849.1	g.chr19:57407794C>T	c.547C>T	p.R183W	Missense
OCC36PT	<i>PPP2RIA</i>	CCDS12849.1	g.chr19:57407791C>T	c.544C>T	p.R182W	Missense

\* Coordinates refer to the human reference genome hg18 release (NCBI 36.1, March 2006).

# Samples OCC01 to OCC08 were used for the initial (discovery) screen for mutations